Down-regulated donor-specific T-cell reactivity during successful tapering of immunosuppression after kidney transplantation

Clinical and Experimental Immunology

Volumn 128, Issue 2, 2002, Pages 388-393

  Van Besouw, N M ^a   Van Der Mast, B J ^a   De Kuiper, P ^a   Smak Gregoor, P J H ^a   Vaessen, Lenard M B ^a   Ijzermans, J N M ^a   Van Gelder, T ^a   Weimar, W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

CTLpf; HTLpf; MLC; Tapering immunosuppression

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TETANUS TOXOID;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MIXED LYMPHOCYTE CULTURE; MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPLEEN CELL; T LYMPHOCYTE;

DOWN-REGULATION; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION IMMUNOLOGY;

EID: 0036098472     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2002.01810.x     Document Type: Article

References (37)

1. Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients
2. A randomized clinical trial of cyclosporine in cadaveric renal transplantation
3. Cyclosporin in cadaveric renal transplantation: One-year follow-up of a multicentre trial
4. Hypertension in renal transplant recipients on cyclosporin A and corticosteroids and azathioprine
5. Cyclosporine nephrotoxicity: Pathogenesis, prophylaxis, therapy, and prognosis
6. Who should be converted from cyclosporine to conventional immunosuppression in kidney transplantation, and why
7. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation
8. Comparison of three immunosuppressive regimens in cadaver renal transplantation: Long-term cyclosporine, short-term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine
9. Long-term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation
10. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction
11. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: Randomised comparison of two cyclosporin regimens
12. Steroid withdrawal in mycophenolate mofetil-treated renal allograft recipients
13. Withdrawal of mycophenolate mofetil in stable renal transplant recipients
14. Weaning of immunosuppression in liver transplant recipients
15. Defining the outcome of immunosuppression withdrawal after liver transplantation
16. Reduction of donor-specific cytotoxic T lymphocyte precursors in peripheral blood of allografted heart recipients
17. Renal transplant patients with steroid withdrawal evaluated longitudinally for their donor-specific cytotoxic T cell reactivity
18. Microchimerism linked to cytotoxic T lymphocyte functional unresponsiveness (clonal anergy) in a tolerant renal transplant recipient
19. Evidence that improved late renal transplant outcome correlates with the development of in vitro donor antigen-specific hyporeactivity
20. Steroid withdrawal and donor-specific hyporeactivity after cadaveric renal allotransplantation on maintenance triple therapy
21. Mutual tolerance after liver and not after heart transplantation? Evaluation of patient-anti-donor and donor-anti-patient responses by mixed lymphocyte culture
22. Evidence that human cardiac allograft acceptance is associated with a decrease in donor-reactive helper T lymphocytes
23. Donor-specific hyporeactivity after liver transplantation: Prominent decreases in donor-specific cytotoxic T lymphocyte precursor frequencies independent of changes in helper T lymphocyte precursor frequencies or suppressor cell activity
24. Evidence that functional deletion of donor-reactive T lymphocytes in kidney allograft recipients can occur at the level of cytotoxic T cells, IL-2-producing T cells, or both. A limiting dilution study
25. Rebound effect of the allogenic T-cell response to donor and third-party lymphocytes after cyclosporine withdrawal in renal transplant recipients
26. Weaning of immunosuppression in long-term recipients of living related renal transplants: A preliminary study
27. Donor-specific T-cell reactivity identifies kidney transplant patients in whom immunosuppressive therapy can be safely reduced
28. A rapid limiting dilution assay for measuring frequencies of alloreactive, interleukin-2-producing T cells in humans
29. Limiting dilution assays. Experimental design and statistical analysis
30. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression
31. Sequential mixed lymphocyte culture after kidney transplantation: Induction of tolerance or sensitization
32. Clinical significance of in vitro donor-specific hyporesponsiveness in renal allograft recipients as demonstrated by the MLR
33. Cell-mediated immune responses in renal transplant recipients treated with cyclosporin and prednisolone with or without azathioprine
34. Induction of donor-specific tolerance or sensitization as measured by sequential MLC reactivity up to 24 months after renal transplantation
35. Selective reduction of donor-specific cytotoxic T lymphocyte precursors in patients with a well-functioning kidney allograft
36. Decreased donor-specific cytotoxic T cell precursor frequencies one year after clinical lung transplantation do not reflect transplantation tolerance: A comparison of lung transplant recipients with or without bronchiolitis obliterans syndrome
37. Immunologic function and survival in hemodialysis patients